The global spine biologics market is expected to reach $2.7 billion by 2024, increasing at a 4.4 percent compound annual growth rate, according to a Data Bridge Market Research report.

Judge Brouck Jacobs ordered the Columbia-based University of Missouri to comply with a discovery request of its biojoint surgery records, according to the Columbia Tribune.

Japan approved Stemirac, a stem cell treatment for spinal cord injuries, Nature reports.

Asterias Biotherapeutics conducted a clinical trial to study the effectiveness of its OPC1 cells, Seeking Alpha reports. The company released its one-year results.

The American Association of Hip and Knee Surgeons does not currently recommend biologic treatments for advanced hip or knee arthritis, according to a new position statement.

Broomfield, Colo.-based Centeno-Schultz Clinic's Christopher J. Centeno, MD, is urging Colorado legislators to crackdown on unregulated stem cell treatments, The Denver Channel reports.

Rancho Mirage, Calif.-based Star Ortho is now offering Lipogems as an alternative or supplement to orthopedic surgery.

The global biomaterials market is predicted to reach more than $173 billion by 2022, growing at a 16 percent compound annual growth rate, according to a Market Research Engine report.

More and more surgeons are beginning to talk about biologics, stem cells and regenerative medicine. Sameer Mathur, MD, an orthopedic surgeon, explains the future of stem cells in a sponsored article with WRAL.com.

Bert Mandelbaum, MD, described the evidence supporting orthobiologic treatments for torn anterior cruciate ligaments in a Medscape column.

Anika Therapeutics will showcase its Hyalofast cartilage repair scaffold at the 2019 International Cartilage Repair Society Summit in San Diego, Jan. 17-18.

Hughston Clinic of Columbus (Ga.) orthopedic surgeon Champ Baker Jr., MD, implemented Lipogems technology to help repair patients' damaged tissue.

SPR Therapeutics appointed Peter Staats, MD, to chief medical advisor.

Stuart Miller, MD, is an orthopedic surgeon at MedStar Union Memorial Hospital and assistant professor at Johns Hopkins University School of Medicine, both based in Baltimore.

Biogennix named Michael Roux as the orthobiologic company's new general manager.

The global platelet rich plasma market is expected to hit $400 million by 2023, growing at a 13.3 percent compound annual growth rate, according to a Qurate Business Intelligence report.

The global orthopedic biomaterials market is expected to grow at a 7 percent compound annual growth rate between 2018 and 2022, according to a Technavio report.

Bioventus launched its Osteomatrix+ bone graft for various spine and orthopedic applications.

Orthopedic fixation company Ossio received FDA 510(k) clearance for its Ossiofiber Bone Pin Family.

Marco Rodriguez, MD, founder of Baton Rouge, La.-based International Spine Institute, is using regenerative stem cell therapies as an alternative to spinal surgery.